The Health and Human Services Department is withdrawing a proclamation broadly calling on drugmakers to offer hotly contested price discounts for low-income health-care providers in an attempt to fend off litigation, but the agency won’t back down from fighting individual companies.
The HHS’ 2020 advisory opinion calling on pharmaceutical companies participating in the government’s 340B program to deliver drugs purchased by health centers to their contract pharmacies has been withdrawn in the “interest of avoiding confusion and unnecessary litigation,” the agency said in a June 18 court filing.
The withdrawal, however, “does not impact the ongoing efforts” to hold ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.